$JSLL PPT conclusion

Jeena Sikho Lifecare Limited has delivered an exceptional operational performance for FY26, with revenue climbing 71% to ₹801.35 Crore and PAT skyrocketing 178% to ₹222.18 Crore. While Q4FY26 net profits showed a temporary sequential decline, this was caused entirely by prudent, non-recurring accounting provisions (~₹21 Crore) linked to their Ind AS transition, performance bonuses, and labor code revisions. The core underlying engine remains robust. The company's capital-light operational model requires an incredibly low investment of only ₹3–4 Lakh per bed. This strategy has fueled an exceptional 3-year average ROCE of 46% while keeping the balance sheet debt-free. By shifting to high-margin cross-selling channels and deploying 561 new operational beds, the business has secured clear revenue pipelines for FY27. Though risks regarding key-man dependency and panel collection timelines exist, the company's aggressive capacity growth, tightening collections, and a rewarding ₹4.50 dividend indicate strong management alignment with shareholders. With the successful migration to mainboard stock exchanges completed, JSLL presents a compelling growth narrative at a dominant margin profile.